SIM
GALT icon

Spark Investment Management’s Galectin Therapeutics GALT Stock Holding History

Spark Investment Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-23,854
Closed -$39K – 792
2015
Q4 		$39K Buy
+23,854
New +$54.6K 0.01% 726

Other funds holding GALT

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Spark Investment Management's GALT Position: Q1 2016 in Review

Spark Investment Management sold out of Galectin Therapeutics (GALT) in Q1 2016, closing a stake of 23,854 shares — an estimated $39K sold.

Spark Investment Management first reported a position in GALT in Q4 2015 and held it in 1 quarter. The position peaked at $39K in Q4 2015. 50 funds tracked by Wall St. Rank hold GALT as of Q1 2016.

  • Spark Investment Management reported no remaining Galectin Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Spark Investment Management sold 23,854 Galectin Therapeutics shares in Q1 2016, an estimated $39K.
  • Spark Investment Management first reported a position in Galectin Therapeutics in Q4 2015 and held it in 1 quarter.
  • Spark Investment Management's Galectin Therapeutics position peaked at $39K in Q4 2015.
  • 50 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2016.

Based on Spark Investment Management's 13F filing for Q1 2016, filed 12 May 2016.